Amorcyte - Cell Therapy Solutions for Cardiovascular Disease

About Amorcyte

Leadership

Investors

Technology

Clinical Trials

Corporate Development

News & Events

Amorcyte, a NeoStem company, develops cell therapy products to treat cardiovascular disease.

Its lead product candidate, AMR-001, for the prevention of major adverse cardiac events following acute myocardial infarction (AMI), has completed Phase I clinical trials demonstrating feasibility, safety and biologic activity at a threshold dose. This is the first prospective stem cell trial in AMI ever conducted that has established a statistically significant relationship between dose and effect. Amorcyte is now open for enrollment of patients for the PreSERVE AMI Phase II trial. The trial has been designed to evaluate the potential of AMR-001 to improve perfusion, preserve cardiac function and improve clinical outcomes.

Amorcyte will be provided with a pharmaceutical grade cGMP manufactured product that can be distributed commercially by Progenitor Cell Therapy, another NeoStem company and a leading provider of clinical, manufacturing and other services for the cell therapy industry.

Click here, to download a fact sheet on Amorcyte and AMR-001.

AMORCYTE, A NEOSTEM COMPANY, ENROLLS FIRST PATIENT IN PRESERVE PHASE 2 TRIAL FOR ACUTE MYOCARDIAL INFARCTION

New York, NY (January 25, 2012)

SENIOR MANAGEMENT OF NEOSTEM AND ITS SUBSIDIARIES INVITED TO SPEAK AT SEVENTH INTERNATIONAL CONFERENCE ON CELL THERAPY FOR CARDIOVASCULAR DISEASE

New York, NY January 23, 2012)

AMORCYTE, A NEOSTEM COMPANY, ANNOUNCES EXPANSION OF INTELLECTUAL PROPERTY

New York, NY (January 10, 2012)

NEOSTEM ACQUIRES AMORCYTE, A CLINICAL STAGE CARDIOVASCULAR DISEASE CELL THERAPY COMPANY

New York, NY, October 17, 2011)

NEOSTEM PROVIDES UPDATE ON AMORCYTE CLINICAL PROGRESS AND REPORTS RESULTS FOR SECOND QUARTER

New York, NY, August 15, 2011

NEOSTEM SIGNS DEFINITIVE MERGER AGREEMENT TO ACQUIRE AMORCYTE IN EQUITY TRANSACTION

New York, NY, July 14, 2011

AMORCYTE STEM CELL THERAPY DEMONSTRATES CLINICALLY SIGNIFICANT REPERFUSION IN SEVERE HEART ATTACK PATIENTS

American Heart Journal Publication Establishes Achievement of Threshold Dose

Allendale, NJ, December 21, 2010